Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ayala Pharmaceuticals
Biotech
Immunome's desmoid tumor treatment triumphs in phase 3
The therapy cut the risk of disease progression or death by 84% for patients with desmoid tumors, data one analyst calls a “near best-case outcome.”
Gabrielle Masson
Dec 15, 2025 10:42am
OS buys full IP rights to its lead drug, gains 2 more assets
Jan 29, 2025 10:30am
Immunome pays $50M for Ayala's phase 3 desmoid tumor drug
Feb 6, 2024 9:50am
Ayala, Advaxis merger means new leadership team—Chutes & Ladders
Oct 21, 2022 9:30am
Ayala and Advaxis fuse together to pool funds for lead programs
Oct 19, 2022 11:00am
Ayala's ex-BMS drug shows promise in triple-negative breast cancer
Jun 2, 2019 9:00am
